Interaction between statins and clopidogrel: is there anything clinically relevant?
Authors:
- O. OrmerodOOO. Ormerod
- J. NewtonJNJ. Newton
- A.P. BanningABA.P. Banning
- L. TestaL. Testa
- 1 August 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 101 (12) , 915-925
Abstract
Since their introduction several years ago, the 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors—the statins—have been widely used for hyperlipidemia and for the primary/secondary prevention of cardiovascular diseases. They have been shown to be safe as well as efficacious in a number of different clinical trials; however, studies have suggested that they can interact with other co-administered therapies. More recently, the thienopyridines have been successfully integrated with the conventional medical treatment of coronary disease as they showed effectiveness in reducing platelet activity both in stable and unstable settings. They also improve the outcome of patients treated with percutaneous coronary intervention. The potential interaction of statins and thienopyridines is a matter of concern. Despite some preclinical data suggesting an interaction between statins metabolized by the liver cytochrome P3A4—such as atorvastatin, lovastatin and simvastatin—and clopidogrel, there is no compelling clinical evidence to stop their co-administration.Keywords
This publication has 48 references indexed in Scilit:
- Systematic Overview of Warfarin and Its Drug and Food InteractionsArchives of internal medicine (1960), 2005
- Women’s Ischemic Syndrome EvaluationCirculation, 2004
- Cerivastatin and Reports of Fatal RhabdomyolysisNew England Journal of Medicine, 2002
- Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment ElevationNew England Journal of Medicine, 2001
- Structural Mechanism for Statin Inhibition of HMG-CoA ReductaseScience, 2001
- Effect of Statins on Risk of Coronary DiseaseJAMA, 1999
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995